Clinical Scorecard: Ocular Adverse Effects Linked to Antibody-Drug Conjugates in Cancer Treatment: An In-Depth Analysis
At a Glance
Category
Detail
Condition
Ocular toxicity induced by antibody-drug conjugates (ADCs) in cancer therapy
Key Mechanisms
Targeted delivery of cytotoxic payloads by ADCs leads to ocular toxicity primarily driven by payload-induced damage, including microtubule inhibition and DNA damage affecting ocular tissues
Target Population
Cancer patients receiving ADC therapy
Care Setting
Oncology clinical settings including clinical trials and routine cancer treatment
Key Highlights
Ocular toxicity is a significant dose-limiting adverse event for several ADCs, impacting visual function and treatment adherence.
Payload type (microtubule inhibitors or DNA-damaging agents) is the primary contributor to ADC-associated ocular toxicity.
FDA boxed warnings exist for belantamab mafodotin, tisotumab vedotin, and mirvetuximab soravtansine due to ocular adverse events.
Guideline-Based Recommendations
Diagnosis
Early detection of ocular toxicity through regular ophthalmologic assessments during ADC therapy.
Management
Implement toxicity management strategies including dose modification, treatment interruption, or discontinuation based on severity of ocular adverse events.
Consider supportive ocular treatments to mitigate symptoms and preserve visual function.
Monitoring & Follow-up
Continuous monitoring of visual function and ocular symptoms throughout ADC treatment to prevent irreversible damage.
Use clinical trial and postmarketing surveillance data to inform monitoring frequency and interventions.
Risks
High incidence of ocular adverse events can lead to premature treatment discontinuation in over 50% of affected patients.
Potential for significant visual impairment impacting quality of life.
Patient & Prescribing Data
Patients undergoing treatment with FDA-approved ADCs for various cancers
Ocular adverse events are common and may necessitate treatment modifications; awareness and proactive management are essential to maintain adherence and optimize outcomes.
Clinical Best Practices
Educate patients on potential ocular symptoms and encourage prompt reporting.
Integrate multidisciplinary care involving oncologists and ophthalmologists for comprehensive management.
Tailor ADC dosing and scheduling to balance efficacy with ocular toxicity risk.
Leverage drug development strategies such as optimized linker design and payload selection to reduce ocular toxicity.
